HEOR

Unleashing the Value of Innovative Healthcare Technologies

Conquering the Unimaginable

We're motivated by the urgency to generate robust and differentiated value for innovative healthcare technologies entering the market. As a leading value science company, Syenza offers integrated HEOR services that create credible value for our clients. Our unparalleled scientific, strategic, and operational capacity magnify the value of our clients' assets in the Pharma, Medtech, and Biotech industries.

HEOR

Value Communications

Syenza develops agile, tech-enabled Global Value Dossiers and localized HTA submissions to set in motion the value of innovative healthcare technologies. Our GVDs and HTA submissions strengthen the interlinkages between the clinical, economic and humanistic outcomes to facilitate decision-making.

Health Economic Analyses

Syenza reveals the differentiated value of innovations by determining the comprehensive health economic impact of healthcare technologies. Our interactive cost-effectiveness and budget impact models are validated before they inform decision-making on the value and affordability of innovations.

Scientific Writing

Syenza is more than just medical writers; we are Scientific Partners for your Business. Our innovative, fit-for-purpose publication strategies deliver high-quality evidence synthesis for early value communication, payor engagement, critical assessment of clinical and economic outcomes, horizon scanning, and targeted evidence reviews.

Service Outcomes

Clients receive actionable insights in Cost-Effectiveness and Budget Impact Technical Reports with a complete Dynamic Model.
Clients deploy our insights to guide the development of GVDs and submissions to HTA agencies.
Clients integrate publishable systematic literature reviews, burden of illness studies, manuscripts, abstracts, and posters.

View Our Recent Case Study

Biopharmaceutical Cost-Effectiveness Analysis in South Africa

January 27, 2023

Objective : The client is committed to advancing care for patients around the world by bringing forward medicines in areas of unmet medical need. They do this through internal research and development, as well as through collaborations with academic

Read More

VIEW ALL

View Our Recent Articles

RSS Health economic evaluations – Syenza News
  • EU Launches Joint Scientific Consultations to Enhance Health Technology Assessment January 14, 2026
    Are your clinical studies ready for EU-wide HTA alignment? The European Commission has opened the first 2026 submission window for Joint Scientific Consultations (Jan 7–Feb 4, 2026) — a free opportunity to get early HTA input (including parallel EMA coordination) that helps design studies fit for Joint Clinical Assessments and smoother market access. Aligning evidence […]
    João L. Carapinha
  • NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leukaemia November 25, 2025
    Could a UK-developed CAR T therapy significantly improve survival for adults with relapsed B‑cell ALL? 🧬 NICE has recommended obecabtagene autoleucel for adults aged 26+ (subject to a commercial deal), finding improved event‑free and overall survival versus blinatumomab, inotuzumab and ponatinib and cost‑effectiveness within NHS thresholds — though it’s not recommended for 18–25s due to […]
    João L. Carapinha
  • Health Investment Returns: Harnessing Health as a Strategic Economic Asset November 18, 2025
    Can health be a nation's most strategic asset? 💡📈 EFPIA’s guest analysis reframes health spending as high-return investment—showing how targeted innovation and earlier care (notably for HER2+ breast cancer) can reduce disease-driven productivity losses, unlock trillions in GDP, and deliver up to $4 back per $1 spent. It also outlines HEOR methods and policy shifts […]
    João L. Carapinha
VIEW ALL